Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

A Phase II Trial Evaluating the Efficacy and Safety of Sargramostim Post Infusion of T -Replete HLA Mismatched Peripheral Blood Haploidentical Hematopoietic Stem Cells with Post Transplant Cyclophosphamide

Melhem Solh, MD, Scott R. Solomon, MD, H. Kent Holland, MD, Lawrence E Morris, MD, Asad Bashey, MD PhD

Blood (2019) 134 (Supplement_1): 4479.

https://doi.org/10.1182/blood-2019-131624

Published: 2019

Journal Articles

Trends in Neutropenia-Related Hospitalization in Older Patients with Non-Hodgkin Lymphoma (NHL) Receiving Myelosuppressive Chemotherapy in the United States: 1995-2015

Shuling Li, PhD, Jiannong Liu, PhD, Haifeng Guo, MS, Prasad L Gawade, MBBS, PhD, Christopher Kim, PhD, Mark E. Bensink, PhD MSc, MD, David Chandler, PhD

Blood (2018) 132 (Supplement 1): 2308.

https://doi.org/10.1182/blood-2018-99-115213

Published: 2018

Journal Articles

Use and Patterns of Supportive Care Among Patients Receiving Myelosuppressive Chemotherapy for Breast Cancer, Colorectal Cancer, Lung Cancer, or Non-Hodgkin's Lymphoma in US Clinical Practice

Derek Weycker, PhD, Amanda Silvia, BS, Kathryn Richert-Boe, MD MPH, Mark Bensink, PhD MS, James O. Brady, MD, Lois Lamerato, PhD, Heather Lipkovich, MPH, Ahmad Daniyal Siddiqui, MD, David Chandler, PhD MBA

Blood (2016) 128 (22): 5909.

https://doi.org/10.1182/blood.V128.22.5909.5909

Published: 2016

Journal Articles

Sargramostim Accelerates Leukocyte Recovery and Improves Mortality Rate at Day 60 in a Non-Human Primate Model of Hematopoietic Acute Radiation Syndrome When Administered 48 h after Total Body Irradiation

Nicholas P. Clayton, MSc, Eric J.J. Charpentier, MSc, Emily R. LaCasse, BSc, Richard C. Khan-Malek, MS, Joan M. Keutzer, PhD

Blood (2016) 128 (22): 2512.

https://doi.org/10.1182/blood.V128.22.2512.2512

Published: 2016

Journal Articles

Timing of Primary Prophylaxis G-CSF Use during Chemotherapy in Elderly Patients with NHL

Shuling Li, PhD, Iberia Romina Sosa, MD PhD, Julia T Molony, MS, John H Page, MD ScD, Richard L Barron, MS, Jiannong Liu, PhD, Phuong Khanh Morrow, MD, Scott Stryker, MD DrPH, John F Acquavella, PhD, Allan J Collins, MD FACP

Blood (2014) 124 (21): 6013.

https://doi.org/10.1182/blood.V124.21.6013.6013

Published: 2014

Journal Articles

Co-Treatment Of Hairy Cell Leukemia and Melanoma With The BRAF Inhibitor Dabrafenib

Leslie A. Andritsos, MD, James S. Blachly, MD, Kari Kendra, M.D., Gerard Lozanski, M.D., Michael R. Grever, MD

Blood (2013) 122 (21): 5311.

https://doi.org/10.1182/blood.V122.21.5311.5311

Published: 2013

Journal Articles

High Dose Sargramostim (GM-CSF) Combined with IV Plerixafor for the Mobilization of Peripheral Blood Stem Cells (PBSC) From Normal HLA-Matched Allogeneic Sibling Donors Results in Hypercoagulability

Mark A. Schroeder, MD, Sandra Lopez, MD, Michael P. Rettig, PhD, Kathryn Trinkaus, PhD, Peter Westervelt, John F. DiPersio, MD, PhD

Blood (2012) 120 (21): 4095.

https://doi.org/10.1182/blood.V120.21.4095.4095

Published: 2012

Journal Articles

Effect of Age on Neutropenia-Related Hospitalization in Non-Hodgkin's Lymphoma Patients Receiving Myelosuppressive Chemotherapy

Henry J Henk, PhD, Robert G Deeter, PharmD, James A. Kaye, MD, DrPH, Laura K Becker, MS, Jason C Legg, PhD, Kenneth J Rothman, DrPH

Blood (2011) 118 (21): 2082.

https://doi.org/10.1182/blood.V118.21.2082.2082

Published: 2011

Journal Articles

Prospective Study to Evaluate the Efficacy and Safety of Gemcitabine Combined with GMCSF and Rituximab in Heavily Pre-Treated Relapsed / Refractory B-Lymphoproliferative Disorders

Shinoj Pattali, MD, Stephanie A. Gregory, Melissa Leigh Larson, MD, Jamile M. Shammo, MD, Elena Bogdanova, CCRP, Teresa Obrien, RN, BS, Parameswaran Venugopal, MD

Blood (2011) 118 (21): 1616.

https://doi.org/10.1182/blood.V118.21.1616.1616

Published: 2011

Journal Articles

Phase I-II Study of Dose Dense PEG-Filgrastim and GM-CSF as Support for Dose Dense CHOP-R Front Line Therapy for Aggressive Non-Hodgkin's Lymphoma (NHL).

Maribel Cotto, MD, Fernando Cabanillas, MD, Idalia Liboy, MD, Ezequiel Rivera, MD, Orestes A. Pavia, MD, Margarita Bruno

Blood (2010) 116 (21): 2789.

https://doi.org/10.1182/blood.V116.21.2789.2789

Published: 2010

Journal Articles

Rituximab Plus CHOP Given Every 15 Days with GM-CSF (sargramostim) In Patients Withnewly Diagnosed Diffuse Large B-Cell Lymphoma

Anil Tulpule, MD, Nancy Berman, Nazish Ahmed, William Boswell, Mary El-Masry, Preet Chaudhary, MD, PhD

Blood (2010) 116 (21): 4886.

https://doi.org/10.1182/blood.V116.21.4886.4886

Published: 2010

Journal Articles

Autologous Hematopoietic Cell Transplantation as Consolidation for Younger Patients with Acute Myeloid Leukemia in First Complete Remission: Follow-up of E1900.

Hugo F. Fernandez, MD, Zhuoxin Sun, Ph.D, Mark R. Litzow, Selina M. Luger, MD, Elisabeth M. Paietta, Gordon W. Dewald, Rhett P. Ketterling, MD, John M Bennett, Jacob M. Rowe, MD, Hillard M. Lazarus, MD, Martin S. Tallman, MD

Blood (2009) 114 (22): 3405.

https://doi.org/10.1182/blood.V114.22.3405.3405

Published: 2009

Journal Articles

Experience with Fludarabine, Cyclophosphamide, Rituximab (FCR) Plus GM-CSF in Frontline Therapy for Chronic Lymphocytic Leukemia (CLL)

Alessandra Ferrajoli, Stefan Faderl, Susan O’Brien, William Wierda, Ana Ayala, Susan Smith, Tiffany C Brown, Hagop Kantarjian, Michael Keating

Blood (2008) 112 (11): 3173.

https://doi.org/10.1182/blood.V112.11.3173.3173

Published: 2008

Journal Articles

Comparison of Infection-Related Hospitalization Risk and Associated Costs among Patients Receiving Sargramostim (Leukine®), Filgrastim (Neupogen®), and Pegfilgrastim (Neulasta®) for Chemotherapy-Induced Neutropenia

Edmond L Toy, PhD, Francis Vekeman, MA, François Laliberté, MA, Bree Dority, PhD, Daniel Perlman, Victoria Barghout, MSPH, Mei Sheng Duh, MPH, ScD, Mark Lawrence Heaney, MD, PhD

Blood (2008) 112 (11): 665.

https://doi.org/10.1182/blood.V112.11.665.665

Published: 2008

Journal Articles

Extreme Leukocytosis in the 21st Century Is Often Iatrogenic

Zachary P. Hugo, MD, Michael C. Perry, MD, David P. Steensma, MD, FACP

Blood (2008) 112 (11): 5401.

https://doi.org/10.1182/blood.V112.11.5401.5401

Published: 2008

Journal Articles

A Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy with Mitumprotimut-T (ID-KLH) and GM-CSF Following Rituximab in Patients with CD20+ Follicular Lymphoma

Arnold S. Freedman, MD, Sattva Neelapu, MD, Craig R Nichols, MD, Michael Robertson, MD, Benjamin Djulbegovic, MD, PhD, Jane N. Winter, MD, Daniel Gold, PhD, John Bender, PharmD, Morgan Stewart, PhD, Richard G. Ghalie, MD, MBA, Paul A. Hamlin, Jr., MD

Blood (2008) 112 (11): 236.

https://doi.org/10.1182/blood.V112.11.236.236

Published: 2008

Journal Articles

Active Immunotherapy with Mitumprotimut-T (FavId®, Id-KLH) Following Rituximab Induction in Patients (pts) with Follicular B-Cell Lymphoma (FL): Progression Free Survival (PFS) at 4-Year Follow Up.

Omer Koc, MD, Charles Redfern, MD, Peter Wiernik, MD, Fred Rosenfelt, MD, Jane Winter, MD, Troy Guthrie, MD, Lawrence Kaplan, MD, Peter Holman, MD, John Densmore, MD, John Hainsworth, MD, Thomas S. Lin, MD, PhD, Rene Castillo, MD, Nalini Janakiraman, MD, John Bender, PharmD

Blood (2007) 110 (11): 2567.

https://doi.org/10.1182/blood.V110.11.2567.2567

Published: 2007

Journal Articles

Continued Late Conversion to Complete Remission (CR/CRu) and Durability of Remission (DUR) in Pts with B-Cell Follicular Lymphoma (FL) Treated with Rituximab Followed by Mitumprotimut-T (Id-KLH, FavId®) Active Immunotherapy.

Omer N. Koc, MD, Charles Redfern, MD, Peter H. Wiernik, MD, Fred Rosenfelt, MD, Jane N. Winter, MD, Troy H. Guthrie, MD, Lawrence Kaplan, MD, Peter Holman, MD, John Densmore, MD, PhD, John Hainsworth, MD, Thomas S. Lin, MD, Rene A. Castillo, MD, Nalini Janakiraman, MD, Richard G. Ghalie, MD

Blood (2007) 110 (11): 3427.

https://doi.org/10.1182/blood.V110.11.3427.3427

Published: 2007

Journal Articles

FCgamma Receptor Polymorphisms Do Not Influence the Outcome of Treatment with Rituximab Followed by Active Immunotherapy with Mitumprotimut-T (FavId®, Id-KLH).

David G. Maloney, MD, PhD, Barbara Pender, Erin McCarthy, Daniel P. Gold, PhD

Blood (2007) 110 (11): 3416.

https://doi.org/10.1182/blood.V110.11.3416.3416

Published: 2007

Journal Articles

Dendritic Cell Reconstitution Following Autologous Stem Cell Transplant with GM-CSF Support for Multiple Myeloma.

Annette J. Schlueter, MD, PhD, Judith K. Glasgow, BS, Werner Wilke, MD, PhD, Jacquie R. Marietta, MS, Raymond J. Hohl, MD, PhD, Thomas H. Carter, MD, PhD, Roger D. Gingrich, MD, PhD, Margarida D. Magalhaes-Silverman, MD

Blood (2007) 110 (11): 951.

https://doi.org/10.1182/blood.V110.11.951.951

Published: 2007

NARROW

A Phase II Trial Evaluating the Efficacy and Safety of Sargramostim Post Infusion of T -Replete HLA Mismatched Peripheral Blood Haploidentical Hematopoietic Stem Cells with Post Transplant Cyclophosphamide

Trends in Neutropenia-Related Hospitalization in Older Patients with Non-Hodgkin Lymphoma (NHL) Receiving Myelosuppressive Chemotherapy in the United States: 1995-2015

Use and Patterns of Supportive Care Among Patients Receiving Myelosuppressive Chemotherapy for Breast Cancer, Colorectal Cancer, Lung Cancer, or Non-Hodgkin's Lymphoma in US Clinical Practice

Sargramostim Accelerates Leukocyte Recovery and Improves Mortality Rate at Day 60 in a Non-Human Primate Model of Hematopoietic Acute Radiation Syndrome When Administered 48 h after Total Body Irradiation

Timing of Primary Prophylaxis G-CSF Use during Chemotherapy in Elderly Patients with NHL

Co-Treatment Of Hairy Cell Leukemia and Melanoma With The BRAF Inhibitor Dabrafenib

High Dose Sargramostim (GM-CSF) Combined with IV Plerixafor for the Mobilization of Peripheral Blood Stem Cells (PBSC) From Normal HLA-Matched Allogeneic Sibling Donors Results in Hypercoagulability

Effect of Age on Neutropenia-Related Hospitalization in Non-Hodgkin's Lymphoma Patients Receiving Myelosuppressive Chemotherapy

Prospective Study to Evaluate the Efficacy and Safety of Gemcitabine Combined with GMCSF and Rituximab in Heavily Pre-Treated Relapsed / Refractory B-Lymphoproliferative Disorders

Phase I-II Study of Dose Dense PEG-Filgrastim and GM-CSF as Support for Dose Dense CHOP-R Front Line Therapy for Aggressive Non-Hodgkin's Lymphoma (NHL).

Rituximab Plus CHOP Given Every 15 Days with GM-CSF (sargramostim) In Patients Withnewly Diagnosed Diffuse Large B-Cell Lymphoma

Autologous Hematopoietic Cell Transplantation as Consolidation for Younger Patients with Acute Myeloid Leukemia in First Complete Remission: Follow-up of E1900.

Experience with Fludarabine, Cyclophosphamide, Rituximab (FCR) Plus GM-CSF in Frontline Therapy for Chronic Lymphocytic Leukemia (CLL)

Comparison of Infection-Related Hospitalization Risk and Associated Costs among Patients Receiving Sargramostim (Leukine®), Filgrastim (Neupogen®), and Pegfilgrastim (Neulasta®) for Chemotherapy-Induced Neutropenia

Extreme Leukocytosis in the 21st Century Is Often Iatrogenic

A Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy with Mitumprotimut-T (ID-KLH) and GM-CSF Following Rituximab in Patients with CD20+ Follicular Lymphoma

Active Immunotherapy with Mitumprotimut-T (FavId®, Id-KLH) Following Rituximab Induction in Patients (pts) with Follicular B-Cell Lymphoma (FL): Progression Free Survival (PFS) at 4-Year Follow Up.

Continued Late Conversion to Complete Remission (CR/CRu) and Durability of Remission (DUR) in Pts with B-Cell Follicular Lymphoma (FL) Treated with Rituximab Followed by Mitumprotimut-T (Id-KLH, FavId®) Active Immunotherapy.

FCgamma Receptor Polymorphisms Do Not Influence the Outcome of Treatment with Rituximab Followed by Active Immunotherapy with Mitumprotimut-T (FavId®, Id-KLH).

Dendritic Cell Reconstitution Following Autologous Stem Cell Transplant with GM-CSF Support for Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only